Concurrent Chemoradiotherapy
Showing 1 - 25 of 3,191
Lung Tumors Trial (Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy), Envafolimab combined
Not yet recruiting
- Lung Neoplasms
- Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy)
- Envafolimab combined with concurrent chemoradiotherapy (Conventional Radiotherapy)
- (no location specified)
Jun 12, 2023
Esophageal Carcinoma Trial in Nanjing (Nimotuzumab, Tigio, Concurrent radiation therapy)
Enrolling by invitation
- Esophageal Carcinoma
- Nimotuzumab
- +2 more
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital of Nanjing Medical University
Sep 19, 2023
Rectal Cancer Trial in Chongqing (CIETAI-R)
Recruiting
- Rectal Cancer
- CIETAI-R
-
Chongqing, Chongqing, ChinaDaping Hospital, Third Military Medical University
Jul 21, 2023
Plasma MRD and cfDNA HPV and Efficacy and Prognosis of Locally
Recruiting
- Locally Advanced Cervical Cancer
- Concurrent chemoradiotherapy
-
Guiyang, Guizhou, ChinaYong Li
Jul 14, 2023
To Evaluate the Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced
Not yet recruiting
- To Evaluate the Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer
- Hydrochloride anlotinib
- +2 more
- (no location specified)
Mar 6, 2023
Esophageal Cancer, Intensity-modulated Radiation Therapy, Concurrent Chemoradiotherapy Trial in Beijing (rhTPO)
Not yet recruiting
- Esophageal Cancer
- +3 more
-
Beijing, Beijing, ChinaDepartment of Radiation Oncology, Cancer Institute and Hospital,
Jul 12, 2023
Nasopharyngeal Carcinoma Trial in Guangzhou, Zhongshan, Nanning (IMRT and concurrent cisplatin, gemcitabine and cisplatin
Not yet recruiting
- Nasopharyngeal Carcinoma
- IMRT and concurrent cisplatin
- gemcitabine and cisplatin (Induction chemotherapy)
-
Guangzhou, Guangdong, China
- +3 more
Jul 30, 2023
Locally Advanced NSCLC, Efficacy and Safety Trial in Guangzhou (Anlotinib, Chemotherapy, Radiotherapy)
Recruiting
- Locally Advanced Non-small Cell Lung Cancer
- Efficacy and Safety
- Anlotinib
- +3 more
-
Guangzhou, Guangdong, ChinaSun yat-sen University Cancer Center
Jul 28, 2022
Uterine Cervical Tumors, Chemoradiotherapy, Adjuvant Chemo Trial in Liuzhou (paclitaxel combined with platinum)
Recruiting
- Uterine Cervical Neoplasms
- +2 more
- paclitaxel combined with platinum
-
Liuzhou, Guangxi, Chinathe Fourth Affiliated Hospital of Guangxi Medical University
Feb 16, 2023
Cervical Cancer Trial in Nanning (tislelizumab, concurrent chemoradiotherapy)
Not yet recruiting
- Cervical Cancer
- tislelizumab
- concurrent chemoradiotherapy
-
Nanning, Guangxi, ChinaFirst Affiliated Hospital of Guangxi Medical University
Aug 22, 2022
Rectal Cancer Trial (fruquintinib + concurrent radiotherapy + chemo)
Not yet recruiting
- Rectal Cancer
- fruquintinib + concurrent radiotherapy + chemotherapy
- (no location specified)
Oct 8, 2022
Cervical Cancer Trial in Shanghai (adjuvant concurrent chemoradiotherapy, radiotherapy)
Recruiting
- Cervical Cancer
- adjuvant concurrent chemoradiotherapy
- radiotherapy
-
Shanghai, Shanghai, China
- +1 more
Sep 14, 2022
Esophageal Squamous Cell Carcinoma Trial in Guangzhou (Split-course hypo-CCRT, Induction chemo-immunotherapy, Concurrent chemo)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Split-course hypo-CCRT
- +2 more
-
Guangzhou, Guangdong, ChinaSun yat-sen University Cancer Center
Aug 26, 2023
Esophageal Squamous Cell Carcinomas, Concurrent Chemoradiotherapy, Immunotherapy Trial (chemo combined with PD-1 inhibitors)
Not yet recruiting
- Esophageal Squamous Cell Carcinomas
- +3 more
- chemotherapy combined with PD-1 inhibitors
- (no location specified)
Nov 17, 2022
Pancreatic Carcinoma Trial in Nanjing (Tislelizumab, Gemcitabine, Nab paclitaxel)
Recruiting
- Pancreatic Carcinoma
- Tislelizumab
- +3 more
-
Nanjing, Jiangsu, ChinaThe Affiliated Nanjing Drum Tower Hospital of Nanjing University
Dec 1, 2022
Esophageal Squamous Cell Carcinoma Trial in Nanjing (Carrelizumab, Paclitaxel injection, Cisplatin)
Enrolling by invitation
- Esophageal Squamous Cell Carcinoma
- Carrelizumab
- +3 more
-
Nanjing, ChinaThe First Affiliated Hospital of Nanjing Medical University
Sep 19, 2023
Nasopharyngeal Carcinoma Trial in Shanghai (Camrelizumab, Nimotuzumab, neoadjuvant chemo and CCRT)
Recruiting
- Nasopharyngeal Carcinoma
- Camrelizumab
- +2 more
-
Shanghai, Shanghai, ChinaFudan Universtiy Shanghai Cancer Centre
Mar 6, 2023
Uterine Cervical Tumors Trial in Nanning (Tislelizumab, DDP synchronous with radiotherapy)
Recruiting
- Uterine Cervical Neoplasms
- Tislelizumab
- DDP synchronous with radiotherapy
-
Nanning, Guangxi, ChinaFirst Affiliated Hospital of Guangxi Medical University
Oct 19, 2022
Head and Neck Tumor, Chemoradiotherapy Trial in Taichung (SZKJT(San-Zhong-Kui-Jian-Tang))
Completed
- Head and Neck Neoplasm
- Chemoradiotherapy
-
Taichung, TaiwanChina Medical University Hospital
Oct 24, 2022
Oral Cavity Squamous Cell Carcinoma Trial in Yichang (Sintilimab, Radiotherapy)
Recruiting
- Oral Cavity Squamous Cell Carcinoma
- Sintilimab
- Radiotherapy
-
Yichang, Hubei, ChinaDepartment of Medical Oncology, Central Hospital of Yichang City
Feb 18, 2023
Metastatic Esophageal Squamous Cell Carcinoma Trial in Guangzhou (Intensity-modulated radiotherapy concurrent with capecitabine)
Recruiting
- Metastatic Esophageal Squamous Cell Carcinoma
- Intensity-modulated radiotherapy concurrent with capecitabine
-
Guangzhou, Guangdong, ChinaSun yat-sen University Cancer center
Aug 21, 2022
Locally Advanced Nasopharyngeal Carcinoma Trial in Sichuan (low-dose radiotherapy)
Recruiting
- Locally Advanced Nasopharyngeal Carcinoma
- low-dose radiotherapy
-
Sichuan, Sichuan, ChinaLow-dose Radiotherapy and Neoadjuvant Chemotherapy Sequential Co
Aug 16, 2022
Esophageal Cancer Trial in Taoyuan (PET/MRI)
Completed
- Esophageal Cancer
- PET/MRI
-
Taoyuan, TaiwanLinkou Chang Gung Memorial Hospital
May 9, 2023